Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing

Principal Investigator

Jeremy Cetnar

Study Purpose

This study is being done to answer the following questions:

1. Does nivolumab in combination with standard chemotherapy work better for treating bladder cancer that has invaded the muscle layer of the bladder?

2. Can we identify a person’s response to treatment with chemotherapy plus nivolumab without needing the bladder removed surgically?

Medical Condition(s)

Muscle-invasive bladder cancer with selective bladder sparing

Eligibility Criteria

1. Age ≥ 18 years at the time of consent
2. Confirmed urothelial cancer of the bladder
3. Eligible for cystectomy

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

You will receive study drug for up to 3 months at which time your tumor will be assessed. If you are eligible, you may receive additional study drug for up to 4 months.

Minors Included



Clinical Trials Information Line: Phone 503-494-1080 or


Sponsor-Investigator - Dr. Galsky (Funded by Bristol-Myers Squibb). He works at the Tisch Cancer Institute.

Recruitment End


Compensation Provided


Go Back